Santen Pharmaceutical (OTCMKTS:SNPHY) Sets New 12-Month High – Still a Buy?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY)’s stock price reached a new 52-week high on Wednesday . The company traded as high as $13.8475 and last traded at $13.4450, with a volume of 502 shares. The stock had previously closed at $13.23.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Santen Pharmaceutical Price Performance

The company has a market capitalization of $4.33 billion and a price-to-earnings ratio of 0.10. The stock has a fifty day simple moving average of $11.63 and a 200-day simple moving average of $11.18.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan?based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over?the?counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post?operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.